214 related articles for article (PubMed ID: 35817022)
21. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
[TBL] [Abstract][Full Text] [Related]
22. Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes.
Rendell MS
Expert Rev Endocrinol Metab; 2018 Nov; 13(6):333-339. PubMed ID: 30379091
[TBL] [Abstract][Full Text] [Related]
23. The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Sargeant JA; King JA; Yates T; Redman EL; Bodicoat DH; Chatterjee S; Edwardson CL; Gray LJ; Poulin B; Waheed G; Waller HL; Webb DR; Willis SA; Wilding JPH; Khunti K; Stensel DJ; Davies MJ
Diabetes Obes Metab; 2022 Aug; 24(8):1509-1521. PubMed ID: 35441435
[TBL] [Abstract][Full Text] [Related]
24. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
Lapuerta P; Urbina S; He J; Wittle A; Li C; Li T; Wang H; Hompesch M
Clin Pharmacol Ther; 2024 Jun; 115(6):1383-1390. PubMed ID: 38456487
[TBL] [Abstract][Full Text] [Related]
25. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
Zambrowicz B; Freiman J; Brown PM; Frazier KS; Turnage A; Bronner J; Ruff D; Shadoan M; Banks P; Mseeh F; Rawlins DB; Goodwin NC; Mabon R; Harrison BA; Wilson A; Sands A; Powell DR
Clin Pharmacol Ther; 2012 Aug; 92(2):158-69. PubMed ID: 22739142
[TBL] [Abstract][Full Text] [Related]
26. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
[TBL] [Abstract][Full Text] [Related]
27. Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.
Takebayashi K; Inukai T
J Clin Med Res; 2017 Sep; 9(9):745-753. PubMed ID: 28811850
[TBL] [Abstract][Full Text] [Related]
28. A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus.
Huang L; Cao B; Geng Y; Zhou X; Yang Y; Ma T; Lin H; Huang Z; Zhuo L; Li J
Eur J Pharm Sci; 2024 Jan; 192():106644. PubMed ID: 37981049
[TBL] [Abstract][Full Text] [Related]
29. Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
Du F; Hinke SA; Cavanaugh C; Polidori D; Wallace N; Kirchner T; Jennis M; Lang W; Kuo GH; Gaul MD; Lenhard J; Demarest K; Ajami NJ; Liang Y; Hornby PJ
J Pharmacol Exp Ther; 2018 Jun; 365(3):676-687. PubMed ID: 29674332
[TBL] [Abstract][Full Text] [Related]
30. Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes.
Danne T; Pettus J; Giaccari A; Cariou B; Rodbard H; Weinzimer SA; Bonnemaire M; Sawhney S; Stewart J; Wang S; Castro RC; Garg SK
Diabetes Technol Ther; 2019 Sep; 21(9):471-477. PubMed ID: 31335194
[No Abstract] [Full Text] [Related]
31. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.
Pitt B; Steg G; Leiter LA; Bhatt DL
Cardiovasc Drugs Ther; 2022 Jun; 36(3):561-567. PubMed ID: 34750713
[TBL] [Abstract][Full Text] [Related]
32. Effects of SGLT2 Inhibitors beyond Glycemic Control-Focus on Myocardial SGLT1.
Sayour AA; Ruppert M; Oláh A; Benke K; Barta BA; Zsáry E; Merkely B; Radovits T
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576016
[TBL] [Abstract][Full Text] [Related]
33. Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis.
Kim YJ; Hwang SD; Lim S
Front Endocrinol (Lausanne); 2020; 11():553. PubMed ID: 32973680
[TBL] [Abstract][Full Text] [Related]
34. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
Park SH; Belcastro E; Hasan H; Matsushita K; Marchandot B; Abbas M; Toti F; Auger C; Jesel L; Ohlmann P; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2021 Mar; 20(1):65. PubMed ID: 33726768
[TBL] [Abstract][Full Text] [Related]
36. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.
Chen HB; Yang YL; Meng RS; Liu XW
ESC Heart Fail; 2023 Apr; 10(2):1231-1241. PubMed ID: 36702979
[TBL] [Abstract][Full Text] [Related]
37. Improved glycemic control in mice lacking Sglt1 and Sglt2.
Powell DR; DaCosta CM; Gay J; Ding ZM; Smith M; Greer J; Doree D; Jeter-Jones S; Mseeh F; Rodriguez LA; Harris A; Buhring L; Platt KA; Vogel P; Brommage R; Shadoan MK; Sands AT; Zambrowicz B
Am J Physiol Endocrinol Metab; 2013 Jan; 304(2):E117-30. PubMed ID: 23149623
[TBL] [Abstract][Full Text] [Related]
38. The journey from gene knockout to clinical medicine: telotristat and sotagliflozin.
Rendell MS
Drug Des Devel Ther; 2019; 13():817-824. PubMed ID: 30880915
[TBL] [Abstract][Full Text] [Related]
39. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
Hira T; Koga T; Sasaki K; Hara H
Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
[TBL] [Abstract][Full Text] [Related]
40. Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.
Højberg PV; Vilsbøll T; Zander M; Knop FK; Krarup T; Vølund A; Holst JJ; Madsbad S
Diabet Med; 2008 Nov; 25(11):1268-75. PubMed ID: 19046215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
